Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunocompromised Swiss Cohorts Based Trial Platform (COVERALL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04805125
Recruitment Status : Recruiting
First Posted : March 18, 2021
Last Update Posted : April 23, 2021
Sponsor:
Collaborator:
Swiss National Science Foundation
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland

Brief Summary:

This study is to set up a flexible trial platform using two existing national cohorts of immunocompromised patients (i.e. Swiss HIV Cohort Study [SHCS] and Swiss Transplant Cohort Study [STCS]) to assess the comparative effectiveness and safety of approved SARS-CoV-2 vaccines in immunocompromised patients.

This platform will be tested in the frame of an exploratory pilot trial and a framework will be set up to conduct a larger, flexible, randomized controlled trial (RCT) to test approved SARS-CoV-2 vaccines to prevent SARS-CoV-2 infections.


Condition or disease Intervention/treatment Phase
Immunocompromised Patients Biological: Moderna COVID-19 Vaccine, mRNA-1273 (100 μg) Biological: Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®) Phase 3

Detailed Description:

This study is to set up a flexible trial platform using two existing national cohorts of immunocompromised patients (i.e. Swiss HIV Cohort Study [SHCS] and Swiss Transplant Cohort Study [STCS]) to assess the comparative effectiveness and safety of approved SARS-CoV-2 vaccines in immunocompromised patients. Nesting this trial into cohorts with highly standardized data collection allows for a rapid, efficient and cost-saving trial conduct.

This platform will be tested in the frame of a pilot trial and a framework will be set up to conduct a larger, flexible, randomized controlled trial (RCT) to test approved SARS-CoV-2 vaccines to prevent SARS-CoV-2 infections.

The pilot study will primarily assess the functionality of the trial platform and early immunogenicity, efficacy and safety data. At a later stage, the platform might also be used to enlarge the pilot trial or to develop sub-protocols to deal with patients with no or insufficient immune response to Sars-CoV-2 vaccines.

Since January 12, 2021 two mRNA vaccines against Sars-CoV-2 by Pfizer / BioNTech (Comirnaty®) and COVID-19 mRNA Vaccine Moderna® by Moderna have been licensed in Switzerland and roll-out of vaccines has started

The first sub-protocol for a pilot trial is to investigate the operability of a platform trial that is nested into two existing cohort studies and compare immune response, safety and clinical efficacy of the first two mRNA vaccines (Comirnaty® by Pfizer / BioNTech and COVID-19 mRNA Vaccine Moderna®, by Moderna) in immune compromised patients in the Swiss HIV and Swiss Transplant Cohort studies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 380 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Cohort embedded platform with a first sub-study pilot trial of two arms comparing licensed vaccines against SARS-CoV-2. The platform design allows to expand the pilot trial into a larger trial by sub-protocols to add or drop vaccine arms or to add further sub-protocols for re-randomization of patients with no immune response to a vaccine booster or new vaccines A parallel two-arm open-label randomized controlled exploratory pilot trial comparing the first in Switzerland approved SARS-CoV-2 vaccines (based on a trial platform that is integrated into the ongoing routine prospective data collection of two national cohorts, the SHCS and STCS).
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Randomised Controlled Trials to Assess Approved SARS-CoV-2 Vaccines in Immunocompromised Patients: A Master Protocol for the Set-up of a Swiss Cohorts Based Trial Platform
Actual Study Start Date : April 19, 2021
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : July 2022

Arm Intervention/treatment
Active Comparator: Moderna mRNA COVID-19 vaccine
The Moderna COVID-19 Vaccine, mRNA-1273 (100 μg) is administered intramuscularly as a series of two doses (0.5 mL each), given 28 days apart.
Biological: Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)
intramuscular injection, proposed as a series of two doses (0.5 mL each), dosing is 100 microgram on day 0 and day 28

Active Comparator: Comirnaty® (Pfizer / BioNTech) mRNA COVID-19 vaccine

Active:

The comparator product is the first licensed vaccine against SARS-CoV-2 in Switzerland.

Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 (30 µg) Comirnaty®, is administered intramuscularly (IM) as a series of two 30 µg doses of the diluted vaccine solution (0.3 mL each) according to the following schedule: a single dose followed by a second dose 21 days later.

Biological: Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)
intramuscular injection, proposed dosing is 30 microgram of the diluted vaccine solution (0.3 mL each) on day 0 and day 21




Primary Outcome Measures :
  1. immunological outcome: change in pan-Ig antibody response (pan-Ig anti-S1-RBD) [ Time Frame: at baseline (day of vaccination) and three months after vaccination ]
    A commercial immunoassay Elecsys® Anti-SARS-CoV-2 S for the in vitro quantitative determination of antibodies to the SARS-CoV-2 spike (S) protein receptor binding domain (RBD) in human serum and plasma is used. This assay detects pan-Ig antibody response (pan-Ig anti-S1-RBD) and allows for a quantitative assessment of the serological response of the participants.

  2. immunological outcome: change in anti-Nucleocapsid (N) response [ Time Frame: at baseline (day of vaccination) and three months after vaccination ]
    Qualitative measurement of anti-Nucleocapsid (N) responses with Elecsys® Anti-SARS-CoV-2 N assay

  3. immunological outcome: change in SARS-CoV-2-binding antibodies [ Time Frame: at baseline (day of vaccination) and three months after vaccination ]
    SARS-CoV-2-binding antibody responses of the participants are assessed by analyzing the IgM, IgA and IgG responses to a wider range of SARS-CoV-2 proteins (S1, S2, RBD and N) using an in-house method (ABCORA). The ABCORA test allows a parallel assessment of IgG, IgM and IgA reactivity.

  4. Number of participants with newly polymerase chain reaction (PCR)-confirmed asymptomatic COVID-19 infection [ Time Frame: at any time point in within 48 weeks following randomisation (day of vaccination) ]
    Number of participants with newly PCR-confirmed asymptomatic COVID-19 infection (identified by the presence of anti-SARS-CoV-2 nucleocapsid antibodies or Sars-Cov-2 PCR or rapid antigen test) and no related symptoms [(i.e. fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose nausea or vomiting, and diarrhea])

  5. Number of participants with newly PCR-confirmed symptomatic COVID-19 infection [ Time Frame: at any time point in within 48 weeks following randomisation (day of vaccination) ]
    Number of participants with newly PCR-confirmed symptomatic COVID-19 infection with at least one of the following symptoms (i.e. fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose nausea or vomiting, and diarrhea

  6. Number of participants with severe COVID-19 infection [ Time Frame: at any time point in within 48 weeks following randomisation (day of vaccination) ]
    Number of participants with severe COVID-19 infection with respiratory failure, evidence of shock (as diagnosed by a treating physician), clinically significant acute renal, hepatic, or neurologic dysfunction; admission to an intensive care unit; or death

  7. Clinical Outcome: COVID-19 burden of diseases (BOD) [ Time Frame: within 48 weeks following randomisation (day of vaccination) ]
    COVID-19 burden of diseases (BOD), a composite, will be scored as by using 0 for no COVID-19, 1 for non-severe COVID-19, and 2 for severe COVID-19.

  8. Duration of RCT set up (specific endpoint related to trial conduct feasibility) [ Time Frame: one time assessment at baseline (from deciding which interventions will be tested until the first patient is randomised) ]
    Duration of RCT set up (i.e. time from deciding which interventions will be tested until the first patient is randomised).

  9. Time of patient recruitment from activation of first study site until 40 patients are randomised [ Time Frame: one time assessment after approx. 3 months (from activation of first study site until 40 patients are randomised) ]
    Time of patient recruitment from activation of first study site until 40 patients are randomised

  10. Time of patient recruitment from activation of first study site until 380 patients are randomised [ Time Frame: one time assessment after approx. 3 months (from activation of first study site until 380 patients are randomised) ]
    Time of patient recruitment from activation of first study site until 380 patients are randomised

  11. Patient consent rate [ Time Frame: approx. 3 months ]
    Patient consent rate (i.e. proportion of patients giving informed consent out of approached eligible patients)

  12. Proportion of missing data for all baseline variables from routinely collected cohort data [ Time Frame: one time assessment at baseline ]
    Proportion of missing data for all baseline variables from routinely collected cohort data

  13. Proportion of missing data for all clinical outcomes [ Time Frame: one time assessment after approx. 3 months ]
    Proportion of missing data for all clinical outcomes from routinely collected cohort data and outcome data that is collected in the trial platform

  14. SARS-CoV-2-specific antibodies [ Time Frame: three months after vaccination ]
    SARS-CoV-2-specific antibodies (using a pan-IgG antibody assay against the receptor binding domain (RBD) against the nP and spike 1 subunits)

  15. SARS-CoV-2-specific titers [ Time Frame: three months after vaccination ]
    SARS-CoV-2-specific titers (using an in-house assay developed by the Institute of Medical Virology, University of Zurich which can detect multiple viral epitopes)


Other Outcome Measures:
  1. Safety Outcome: number of local symptoms [ Time Frame: during the first 7 days after vaccination ]
    Any local symptom (redness or swelling or prolonged pain at injection side) limiting continuation of normal daily activities

  2. Safety Outcome: number of systemic symptoms [ Time Frame: during the first 7 days after vaccination ]
    Any systemic symptom (fever, generalized muscle or joint pain) limiting continuation of normal daily activities

  3. Safety Outcome: number of vaccine related symptoms [ Time Frame: during the first 7 days after vaccination ]
    Any vaccine related symptom leading to contacting a physician

  4. Number of participants with newly PCR-confirmed asymptomatic Covid-19 infection (clinical effectiveness endpoint according to FDA recommendations for phase III Covid-19 vaccine licensing trials) [ Time Frame: at any time points within 48 weeks follow-up ]
    Number of participants with newly PCR-confirmed asymptomatic Covid-19 infection (identified by the presence of anti-SARS-CoV-2 nucleocapsid antibodies, or SARS-CoV-" PCR or rapid antigen test) and no related symptoms [(i.e. fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose nausea or vomiting, and diarrhea])

  5. Newly PCR-confirmed symptomatic Covid-19 infection (clinical effectiveness endpoint according to FDA recommendations for phase III Covid-19 vaccine licensing trials) [ Time Frame: at any time points within 48 week follow-up ]
    Newly PCR-confirmed symptomatic Covid-19 infection with at least one of the following symptoms (i.e. fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose nausea or vomiting, and diarrhea)

  6. Number of participants with severe COVID-19 infection (clinical effectiveness endpoint according to FDA recommendations for phase III Covid-19 vaccine licensing trials) [ Time Frame: at any time points within 48 week follow-up ]
    Number of participants with severe COVID-19 infection with respiratory failure, evidence of shock (as diagnosed by a treating physician), clinically significant acute renal, hepatic, or neurologic dysfunction; admission to an intensive care unit; or death

  7. Covid-19 burden of diseases (BOD) (clinical effectiveness endpoint according to FDA recommendations for phase III Covid-19 vaccine licensing trials) [ Time Frame: within 48 week follow-up ]
    Covid-19 burden of diseases (BOD), a composite of the above endpoints. The BOD will be scored as by using 0 for no COVID-19, 1 for non-severe COVID-19, and 2 for severe COVID-19



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • All patients registered with informed consent from participating cohorts aged ≥18 years
  • Additional consent for participation in the specific sub-protocol trial

Inclusion criteria for pilot trial:

  • All patients with either a chronic HIV infection or recipients of solid organs registered with informed consent from the SHCS and STCS cohorts aged ≥18 years
  • Patients with solid organ transplantation of lungs or kidneys at least one month post-transplantation with a prednisone dose of 20mg or less.
  • Covid-19 vaccination recommended by treating physician

Exclusion criteria:

  • Acute symptomatic SARS-CoV-2 infection, influenza or other acute respiratory tract infection
  • Known allergy or contra-indications for vaccines or any vaccine components
  • Any emergency condition requiring immediate hospitalization for any condition
  • Patients with previous PCR documented SARS-CoV-2 infection and, or documented antibodies less than 3 months prior to screening visit (day 0)

Exclusion criteria for pilot trial:

  • Pregnancy
  • Acute symptomatic SARS-CoV-2 infection, influenza or other acute respiratory tract infection
  • Known allergy or contra-indications for vaccines or any vaccine components
  • Any emergency condition requiring immediate hospitalization for any condition
  • Patients with previous PCR documented SARS-CoV-2 infection and, or documented antibodies less than 3 months prior to randomisation
  • Patients with solid organ transplantation (lung or kidney) with the following conditions:

    1. Solid organ transplant recipients less than one month post-transplantation
    2. Solid organ transplant recipients with the use of T-cell/B-cell depleting agents in the last 3 months (i. e induction treatment in standard risk or high-risk immunological situation or rejection treatment).
    3. Solid organ transplant recipients with the need of pulse corticosteroids (>100mg prednisone or equivalent) in the last 1 month or who have received ATG or rituximab in the last 6 months
    4. Solid organ transplant recipients with the need of any kind of chemotherapy treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04805125


Contacts
Layout table for location contacts
Contact: Heiner C. Bucher, Prof. Dr. med. +41 (0)61 328 61 01 heiner.bucher@usb.ch
Contact: Benjamin Speich, PhD benjamin.speich@usb.ch

Locations
Layout table for location information
Switzerland
University Hospital Basel Recruiting
Basel, Switzerland, 4031
Contact: Heiner C. Bucher, Prof. Dr. med.    +41 (0)61 328 61 01    heiner.bucher@usb.ch   
Sub-Investigator: Benjamin Speich, Dr.         
Principal Investigator: Heiner C. Bucher, Prof.         
Sub-Investigator: Michael Koller, PD Dr. med.         
Sub-Investigator: Matthias Briel, Prof.         
Sub-Investigator: Lars Hemkens, PD Dr. med.         
Sub-Investigator: Michael Tamm, Prof.         
Sub-Investigator: Michael Dickenmann, Prof.         
Sub-Investigator: Marcel Stoeckle, Dr.         
University Hospital Bern Recruiting
Bern, Switzerland, 3010
Contact: Andri Rauch, Prof.       andri.rauch@insel.ch   
Sub-Investigator: Andri Rauch, Prof.         
Sub-Investigator: Anna Lena Eichenberger, Dr.         
University Hospital Lausanne CHUV Not yet recruiting
Lausanne, Switzerland, 1011
Contact: Matthias Cavassini, Prof. Dr. med.    +41 21 314 1022    matthias.cavassini@chuv.ch   
Contact: Oriol Manuel, Prof. Dr. med.         
Sub-Investigator: Matthias Cavassini, Prof.         
Sub-Investigator: Oriol Manuel, Prof.         
University Hospital Zurich Recruiting
Zurich, Switzerland, 8091
Contact: Nicolas Müller, Prof. Dr. med.       nicolas.mueller@usz.ch   
Contact: Macé Schuurmans, PD Dr. med.         
Sub-Investigator: Huldrych Günthard, Prof.         
Sub-Investigator: Nicolas Müller, Prof.         
Sub-Investigator: Thomas Müller, Prof.         
Sub-Investigator: Macé Schuurmans, PD Dr. med.         
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Swiss National Science Foundation
Investigators
Layout table for investigator information
Principal Investigator: Heiner C. Bucher, Prof. Dr. med. Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel
  Study Documents (Full-Text)

Documents provided by University Hospital, Basel, Switzerland:
Study Protocol: Master-Protocol  [PDF] April 7, 2021

Layout table for additonal information
Responsible Party: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT04805125    
Other Study ID Numbers: 2021-000593; me20Bucher
First Posted: March 18, 2021    Key Record Dates
Last Update Posted: April 23, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Basel, Switzerland:
Covid-19 infection
SARS-CoV-2-specific antibodies
Sars-CoV-2 vaccine
vector based messenger ribonucleic acid (mRNA) vaccines
SARS-CoV-2 infection
Swiss HIV Cohort Study [SHCS]
Swiss Transplant Cohort Study [STCS]
Additional relevant MeSH terms:
Layout table for MeSH terms
Vaccines
Immunologic Factors
Physiological Effects of Drugs